A 2026 review of 2020-2025 evidence: biologics (Omalizumab, Mepolizumab, Dupilumab, Tezepelumab) now clinically established for severe Th2-high asthma, while nanoparticle delivery and digital health tools address the adherence and access gaps that pharmacotherapy alone cannot solve.
A comprehensive review of epigenetics from CRISPR-based epigenome editing and single-cell technologies to clinical applications in cancer therapy and aging.
How can nanoparticles deliver drugs to scarred lungs? This review maps the barriers, therapeutic options, and engineering strategies for inhaled nanomedicine in IPF.
Why is delivering RNA to the lungs so hard - and what is the state of the art? This comprehensive review maps every delivery platform from LNPs to exosomes, with clinical trial data and mechanistic deep-dives.
This review covers the latest advances in PROTACs for targeted protein degradation in cancer, from AR and ER degraders in clinical trials to novel E3 ligase strategies.
From alveoli to smart sensors: this review maps the complete landscape of inhaled drug delivery, explaining why the lung route beats oral for rapid action, how DPI/pMDI/SMI devices differ, and what inhaled mRNA, nanoparticles, and vaccines mean for respiratory medicine.
Two-thirds of COPD patients already on maximum therapy achieved meaningful symptom relief with add-on Ensifentrine — the first study targeting this maximally-treated, real-world population.
The largest Bayesian NMA of GLP-1 receptor agonists (64 RCTs, 25,572 patients) identifies tirzepatide as the top-ranked agent for HbA1c reduction and weight loss in T2DM.
This study investigates a TC-NER ERCC6 protein variant (M1097V) prevalent among Louisiana prostate cancer patients, revealing its impact on DNA repair efficiency after UV damage.
